BioStock: Curasight presents brain cancer results at World Molecular Imaging Congress

Curasight resently presented results from the phase II study with uTRACE in brain cancer at the 2023 World Molecular Imaging Congress held in Prague. The study reveals promising data on the effectiveness of uTRACE and thereby also the potential for uTREAT in treating high-grade gliomas. BioStock contacted CEO Ulrich Krasilnikoff to learn more about the results.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/curasight-presents-brain-cancer-results-at-world-molecular-imaging-congress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se